These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 27346829)

  • 61. Gene-Related Response of Basal Cell Carcinoma to Biologic Treatment with Vismodegib.
    Sternfeld A; Rosenwasser-Weiss S; Ben-Yehuda G; Shefer HK; Friedman-Gohas M; Yassur I; Tauber G; Bejar J; Olshinka A; Vardizer Y; Ad El D; Goldenberg-Cohen N
    Sci Rep; 2020 Jan; 10(1):1244. PubMed ID: 31988301
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial.
    Basset-Seguin N; Hauschild A; Grob JJ; Kunstfeld R; Dréno B; Mortier L; Ascierto PA; Licitra L; Dutriaux C; Thomas L; Jouary T; Meyer N; Guillot B; Dummer R; Fife K; Ernst DS; Williams S; Fittipaldo A; Xynos I; Hansson J
    Lancet Oncol; 2015 Jun; 16(6):729-36. PubMed ID: 25981813
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Vismodegib: a review.
    Ruiz-Salas V; Alegre M; López-Ferrer A; Garcés JR
    Actas Dermosifiliogr; 2014 Oct; 105(8):744-51. PubMed ID: 24359667
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Next-generation sequencing of the basal cell carcinoma miRNome and a description of novel microRNA candidates under neoadjuvant vismodegib therapy: an integrative molecular and surgical case study.
    Sand M; Bechara FG; Gambichler T; Sand D; Friedländer MR; Bromba M; Schnabel R; Hessam S
    Ann Oncol; 2016 Feb; 27(2):332-8. PubMed ID: 26578727
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial.
    Basset-Séguin N; Hauschild A; Kunstfeld R; Grob J; Dréno B; Mortier L; Ascierto PA; Licitra L; Dutriaux C; Thomas L; Meyer N; Guillot B; Dummer R; Arenberger P; Fife K; Raimundo A; Dika E; Dimier N; Fittipaldo A; Xynos I; Hansson J
    Eur J Cancer; 2017 Nov; 86():334-348. PubMed ID: 29073584
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Invasive Basal Cell Carcinoma of the Skin Treated Successfully with Vismodegib: A Case Report.
    Awad R; Andrade JCB; Mousa H; Mahmoud F
    Perm J; 2018; 22():17-181. PubMed ID: 30005721
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Experience With Vismodegib in the Treatment of Advanced Basal Cell Carcinoma at a Cancer Center.
    Bernia E; Llombart B; Serra-Guillén C; Bancalari B; Nagore E; Requena C; Calomarde L; Diago A; Lavernia J; Traves V; Guillén C; Sanmartín O
    Actas Dermosifiliogr (Engl Ed); 2018 Nov; 109(9):813-820. PubMed ID: 30055751
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Vismodegib resistant mutations are not selected in multifocal relapses of locally advanced basal cell carcinoma after vismodegib discontinuation.
    Ighilahriz M; Benfodda M; Sharpe H; Soufir N; Mourah S; Dumaz N; Battistella M; Savina A; Bouquet F; Nikolaev S; Basset-Seguin N
    J Eur Acad Dermatol Venereol; 2019 Nov; 33(11):e422-e424. PubMed ID: 31187903
    [No Abstract]   [Full Text] [Related]  

  • 69. [Vismodegib Therapy for Periocular Basal Cell Carcinoma].
    Keserü M; Green S; Dulz S
    Klin Monbl Augenheilkd; 2017 Jan; 234(1):64-69. PubMed ID: 28135752
    [No Abstract]   [Full Text] [Related]  

  • 70. Phase II, Single-Arm Trial of Induction and Concurrent Vismodegib With Curative-Intent Radiation Therapy for Locally Advanced, Unresectable Basal Cell Carcinoma.
    Barker CA; Dufault S; Arron ST; Ho AL; Algazi AP; Dunn LA; Humphries AA; Hultman C; Lian M; Knott PD; Yom SS
    J Clin Oncol; 2024 Jul; 42(19):2327-2335. PubMed ID: 38630954
    [TBL] [Abstract][Full Text] [Related]  

  • 71. 18-FDG PET/CT assessment of basal cell carcinoma with vismodegib.
    Thacker CA; Weiss GJ; Tibes R; Blaydorn L; Downhour M; White E; Baldwin J; Hoff DD; Korn RL
    Cancer Med; 2012 Oct; 1(2):230-6. PubMed ID: 23342272
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.
    Dummer R; Guminski A; Gutzmer R; Dirix L; Lewis KD; Combemale P; Herd RM; Kaatz M; Loquai C; Stratigos AJ; Schulze HJ; Plummer R; Gogov S; Pallaud C; Yi T; Mone M; Chang AL; Cornélis F; Kudchadkar R; Trefzer U; Lear JT; Sellami D; Migden MR
    J Am Acad Dermatol; 2016 Jul; 75(1):113-125.e5. PubMed ID: 27067394
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Treatment of margin positive basal cell carcinoma with vismodegib: case report and consideration of treatment options and their implications.
    Bayers S; Kapp DL; Beer KR; Slavin B
    J Drugs Dermatol; 2013 Oct; 12(10 Suppl):s147-50. PubMed ID: 24085060
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Exploring vismodegib: A non-surgical breakthrough in the management of advanced periocular basal cell carcinoma.
    Lavasidis G; Tzamalis A; Tsinopoulos I; Ziakas N
    Cancer Treat Res Commun; 2024; 39():100796. PubMed ID: 38367414
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Outcomes of Vismodegib for Periocular Locally Advanced Basal Cell Carcinoma From an Open-label Trial.
    Ben Ishai M; Tiosano A; Fenig E; Ben Simon G; Yassur I
    JAMA Ophthalmol; 2020 Jul; 138(7):749-755. PubMed ID: 32407451
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Vismodegib.
    Meiss F; Zeiser R
    Recent Results Cancer Res; 2014; 201():405-17. PubMed ID: 24756807
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Locally advanced basal-cell carcinoma: Combined alternative treatments beyond surgery].
    Amici JM; Beylot-Barry M
    Ann Chir Plast Esthet; 2015 Aug; 60(4):321-5. PubMed ID: 25708732
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Two different scenarios of advanced basal cell carcinomas during the use of vismodegib: Cases of oral administration and administration directly to the stomach.
    Rodríguez-Cerdeira C; Muñoz-Garzón V; González-Cespón JL
    Drug Discov Ther; 2019; 13(2):122-127. PubMed ID: 31080204
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Hedgehog Pathway Inhibition for Locally Advanced Periocular Basal Cell Carcinoma and Basal Cell Nevus Syndrome.
    Ozgur OK; Yin V; Chou E; Ball S; Kies M; William WN; Migden M; Thuro BA; Esmaeli B
    Am J Ophthalmol; 2015 Aug; 160(2):220-227.e2. PubMed ID: 25935097
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Hedgehog Inhibitors Beyond Clinical Complete Response in Basal Cell Carcinoma: Should I Stop or Should I Go?
    Alfieri S; Romanò R; Marceglia S; De Giorgi V; Peris K; Sollena P; Piccerillo A; Moro R; Gualdi G; Ascierto PA; Palla M; Paone M; Eibenschutz L; Spagnolo F; Queirolo P; Filippini DM; Cavalieri S; Resteghini C; Bergamini C; Manocchio A; Licitra L; Bossi P
    Oncologist; 2024 May; 29(5):e699-e707. PubMed ID: 38127280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.